Stock Track | Kiniksa Pharmaceuticals Soars 8.67% in Pre-Market on Raised Revenue Guidance and Strong Q1 Results

Stock Track04-28 19:37

Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 8.67% in pre-market trading on Tuesday.

The surge appears driven by the company's raised revenue guidance for its Arcalyst product and strong first-quarter financial results. Kiniksa Pharmaceuticals raised its 2026 Arcalyst net product revenue guidance to $930-$945 million, indicating confidence in future sales growth.

The company also reported robust Q1 performance with product revenue of $214.266 million, pretax profit of $32.681 million, net income of $22.592 million, and earnings per share of $0.27. Additionally, the company provided an update on its KPL-387 drug candidate, with Phase 2 data expected in the second half of 2026 and Phase 3 trial initiation planned by year-end.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101282237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101282237","market":"nz","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Soars 8.67% in Pre-Market on Raised Revenue Guidance and Strong Q1 Results","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 8.67% in pre-market trading on Tuesday.</p><p>The surge appears driven by the company's raised revenue guidance for its Arcalyst product and strong first-quarter financial results. Kiniksa Pharmaceuticals raised its 2026 Arcalyst net product revenue guidance to $930-$945 million, indicating confidence in future sales growth.</p><p>The company also reported robust Q1 performance with product revenue of $214.266 million, pretax profit of $32.681 million, net income of $22.592 million, and earnings per share of $0.27. Additionally, the company provided an update on its KPL-387 drug candidate, with Phase 2 data expected in the second half of 2026 and Phase 3 trial initiation planned by year-end.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Soars 8.67% in Pre-Market on Raised Revenue Guidance and Strong Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Soars 8.67% in Pre-Market on Raised Revenue Guidance and Strong Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 8.67% in pre-market trading on Tuesday.</p><p>The surge appears driven by the company's raised revenue guidance for its Arcalyst product and strong first-quarter financial results. Kiniksa Pharmaceuticals raised its 2026 Arcalyst net product revenue guidance to $930-$945 million, indicating confidence in future sales growth.</p><p>The company also reported robust Q1 performance with product revenue of $214.266 million, pretax profit of $32.681 million, net income of $22.592 million, and earnings per share of $0.27. Additionally, the company provided an update on its KPL-387 drug candidate, with Phase 2 data expected in the second half of 2026 and Phase 3 trial initiation planned by year-end.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1101282237","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101282237","pubTimestamp":1777376277,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 8.67% in pre-market trading on Tuesday.The surge appears driven by the company's raised revenue guidance for its Arcalyst product and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals盘前大涨8.67%营收指引上调Q1业绩强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 8.67% in pre-market trading on Tuesday.The surge appears driven by the company's raised revenue guidance for its Arcalyst product and strong first-quarter financial results. Kiniksa Pharmaceuticals raised its 2026 Arcalyst net product revenue guidance to $930-$945 million, indicating confidence in future sales growth.The company also reported robust Q1 performance with product revenue of $214.266 million, pretax profit of $32.681 million, net income of $22.592 million, and earnings per share of $0.27. Additionally, the company provided an update on its KPL-387 drug candidate, with Phase 2 data expected in the second half of 2026 and Phase 3 trial initiation planned by year-end.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101282237","isCrawlerRequest":true}